United States of America, ex rel, et al v. Novartis Pharmaceuticals Corporation

  1. May 29, 2014

    NY Judge Won't Toss FCA Kickback Suit Against Novartis

    A New York federal judge on Thursday tentatively denied Novartis Pharmaceuticals Corp.'s bid to toss a False Claims Act lawsuit accusing it of paying kickbacks to specialty pharmacies to push drugs like Exjade and Myfortic, saying more briefing on the issues will be necessary.

  2. April 22, 2014

    CVS Decries Novartis Kickback Suit As 'Implausible'

    CVS Caremark Corp. asked a New York federal judge on Monday to toss a False Claims Act whistleblower suit alleging CVS accepted kickbacks from Novartis Pharmaceutical Corp. to push leukemia drugs Gleevec and Tasigna and cystic fibrosis drug TOBI, calling the claims "fundamentally implausible."

  3. January 27, 2014

    Wash. Joins Suit Over Novartis Exjade Kickbacks

    The state of Washington on Friday intervened in a False Claims Act whistleblower case against Novartis Pharmaceuticals Corp. for allegedly paying kickbacks to a specialty pharmacy to keep patients on its iron reduction drug Exjade, saying it hopes to recoup the Medicaid funds it lost.

  4. January 08, 2014

    BioScrip Agrees To Pay $15M In FCA Kickback Suit

    BioScrip Inc. has agreed to pay $15 million to exit a False Claims Act whistleblower suit alleging it received kickbacks from Novartis Pharmaceuticals Corp. to push patients to continue using Novartis' iron reduction drug Exjade, according to authorities and court documents filed in New York federal court Wednesday.